One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to Gastroenterology
- Development and validation of a test to monitor endoscopic activity in patients with Crohn's disease based on serum levels of proteins.Gastroenterology. 2020; 158: 515-526
- Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): determining therapeutic goals for treat-to-target.Am J Gastroenterol. 2015; 110: 1324-1338
- Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial.Lancet. 2017; 390: 2779-2789
- Sa1812 – endoscopic and deep remission at 1 year prevents disease progression in early Crohn's disease: long-term data from CALM.Gastroenterology. 2019; 156: S-411
- Colorectal cancer screening: recommendations for physicians and patients from the U.S. Multi-Society Task Force on Colorectal Cancer.Gastroenterology. 2017; 153: 307-323
- C-reactive protein, fecal calprotectin, and stool lactoferrin for detection of endoscopic activity in symptomatic inflammatory bowel disease patients: a systematic review and meta-analysis.Am J Gastroenterol. 2015; 110 (quiz 20): 802-819
- Serum calprotectin: a novel diagnostic and prognostic marker in inflammatory bowel diseases.Am J Gastroenterol. 2016; 111: 1796-1805
- Serum calprotectin as a biomarker for Crohn's disease.J Crohns Colitis. 2013; 7: e678-e683
- EMerging BiomARKers in Inflammatory Bowel Disease (EMBARK) study identifies fecal calprotectin, serum MMP9, and serum IL-22 as a novel combination of biomarkers for Crohn's disease activity: role of cross-sectional imaging.Am J Gastroenterol. 2013; 108: 1891-1900
- Serum MMP-9: a novel biomarker for prediction of clinical relapse in patients with quiescent Crohn's disease, a post hoc analysis.Ther Adv Gastroenterol. 2019; 12 (1756284819881590)
- Agreement between home-based measurement of stool calprotectin and ELISA results for monitoring inflammatory bowel disease activity.Clin Gastroenterol Hepatol. 2017; 15: 1742-1749.e2
Conflicts of interest The authors have made the following disclosures: MA receives intramural research support from the Dickler Family Fund. RCU has served as a consultant and/or advisory board member for Eli Lilly, Janssen, Pfizer and Takeda. He has received research support from AbbVie , Boehringer Ingelheim and Pfizer . He is supported by Career Development Awards from the Crohn's and Colitis Foundation and the National Institutes of Health ( K23KD111995-01A1 ). JFC reports receiving research grants from AbbVie, Janssen Pharmaceuticals and Takeda; receiving payment for lectures from AbbVie, Amgen, Allergan, Inc. Ferring Pharmaceuticals, Shire, and Takeda; receiving consulting fees from AbbVie, Amgen, Arena Pharmaceuticals, Boehringer Ingelheim, Celgene Corporation, Celltrion, Eli Lilly, Enterome, Ferring Pharmaceuticals, Genentech, Janssen Pharmaceuticals, Landos, Ipsen, Medimmune, Merck, Novartis, Pfizer, Shire, Takeda, Tigenix, Viela bio; and hold stock options in Intestinal Biotech Development and Genfit. The PREDICT consortium to study preclinical biomarkers associated with IBD, led by Dr Colombel, is supported in part by Prometheus Laboratories Inc., San Diego, California.